



DuPont Central Research and Development



8EHQ-94-13219  
INIT 10/12/94

DuPont Central Research and Development  
Haskell Laboratory for Toxicology and Industrial Medicine  
P.O. Box 50, Elkton Road  
Newark, DE 19714-0050  
Fax: (302) 366-5207

8EHQ-1074-13219  
A

October 12, 1994

ORIGINAL

EXPRESS MAIL-RETURN RECEIPT REQUESTED



88950000009

Document Processing Center (TS - 790)  
Attention: 8(e) Coordinator  
Office of Pollution Prevention and Toxics  
U. S. Environmental Protection Agency  
401 M Street SW  
Washington, D.C. 20460

Contains No CBI

Dear 8(e) Coordinator:

Recently we had occasion to review a pre-1977 (1954) report on the compound nitrocyclohexane (CAS No. 1122-60-7). The report summarizes several different pre-1977 studies performed with this compound. The observations noted in this report which are pertinent to this letter are:

Acute Oral Toxicity - The approximate lethal dose (ALD) was 300 mg/kg of body weight. Lethal doses caused severe convulsions within five to fifteen minutes after dosing. Pathologic examination of animals that died showed congestion of the brain, pointing to a central nervous system effect consistent with the observed convulsions.

Subacute Oral Toxicity - Six rats were dosed daily, five times a week for two weeks with 60 mg/kg of body weight of nitrocyclohexane. One rat had violent convulsions after the first dose and died; pathologic examination suggest that the test compound may have been aspirated into the lung during treatment. Two rats showed tremors for one hour following the last three treatments and one rat had convulsions after the seventh dose. Pathologic examination of the five surviving rats showed no gross effects.

Acute Inhalation Toxicity - The approximate lethal concentration (ALC) was 200-600 ppm (nominal concentrations) in groups of one or two rats. Lethal doses caused convulsions and pathologic examination revealed congestion of the brain.

These observations appear to meet the reporting thresholds as found in the June, 1991 "EPA TSCA Section 8(e) Reporting Guide". Submission of this information is not an admission that DuPont considers the information to "reasonably support a conclusion" of a substantial risk.

Sincerely,

*A. Michael Kaplan* for CFR

Charles F. Reinhardt, M.D.  
Director

CFR/AON:dj  
(302)366-5285

12/16/94